Skip to main content

Table 1 Clinicopathological characteristics of patient samples and expression of PLOD2 in laryngeal cancer

From: PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

Parameters Number of cases (%)
Gender
 Male 106 (93.0)
 Female 8 (7.0)
Age (years)
  < 62 56 (49.1)
  ≥ 62 58 (50.9)
Clinical stage
 I 38 (33.3)
 II 16 (14.0)
 III 28 (24.6)
 IV 32 (28.1)
T classification
 T1& T2 59 (51.8)
 T3 29 (25.4)
 T4 26 (22.8)
N classification
 N0 86 (75.4)
 N1& N2& N3 28 (24.6)
M classification
 No 103 (90.4)
 Yes 11 (9.6)
Thyroid cartilage invasion
 No 88 (77.2)
 Yes 26 (22.8)
Type
 Supraglottic 35 (30.7)
 Subglottic 4 (3.5)
 Glottic 74 (64.9)
 Transglottic 1 (0.9)
Expression of CD44
 Low expression 57 (50.0)
 High expression 57 (50.0)
Expression of CD133
 Low expression 62 (54.4)
 High expression 52 (45.6)
Relapse status (at follow-up)
 No 78 (68.4)
 Yes 36 (31.6)
Vital status (at follow-up)
 Alive 93 (81.6)
 Dead 21 (18.4)
Expression of PLOD2
 Low expression 59 (51.8)
 High expression 55 (48.2)